COSCIENS Biopharma Inc. (AEZS)

COSCIENS Biopharma Inc. (AEZS)
- Cap: $7M
- View AEZS Profile
- View Questions on AEZS

{tplLang.businessdescription | toLang tLang}

{ profileData.description }

{tplLang.details | toLang tLang}

{tplLang.ceo | toLang tLang}

{profileData.profile.details.ceo}

{tplLang.employees | toLang tLang}

{profileData.profile.details.employees | numeraljs '0,0'}

{tplLang.issuetype | toLang tLang}

{profileData.profile.details.issuetype | asIssueType}

{tplLang.industryclassifications | toLang tLang}

{tplLang.sector | toLang tLang}

{profileData.profile.classification.sector}

{tplLang.industry | toLang tLang}

{profileData.profile.classification.industry}

{tplLang.toolname| toLang tLang}

There is no {tplLang.toolname| toLang tLang} currently available for {data.symbolstring}.

COSCIENS Biopharma Inc. (AEZS)
- Cap: $7M
- View AEZS Profile
- View Questions on AEZS

Q: Any idea why this is dropping so drastically following the CZO merger?

Read Answer Asked by Rick on June 21, 2024

Ceapro Inc. (CZO $0.23)
- $0.23 Cap: $17M
- View CZO Profile
- View Questions on CZO
COSCIENS Biopharma Inc. (AEZS)
- Cap: $7M
- View AEZS Profile
- View Questions on AEZS

Q: Hello 5i. Could you comment on the merger of CZO and AEZS . I am currently a holder of CZO and would have a profit if I sold at the current price. I am wondering if I should be happy with my CZO profit and sell or do you think that there will be upside in the merged company.

Read Answer Asked by Michael on March 25, 2024

COSCIENS Biopharma Inc. (AEZS)
- Cap: $7M
- View AEZS Profile
- View Questions on AEZS

Q: Analysts have recently become quite positive about AEZS. Morningstars sees 38 per cent upside to fair value; Thomson Reuters rates is a 10/10 with a trailing P/E of 5.7 with a net margin of 34 per cent. Has your opinion changed since your last reply?

Thank you.

Read Answer Asked by Kurt W on November 29, 2018